Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | SI | P14410 | 2/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5442037 | 0.85 | CA9 (0.44) | GPBAR1LMNANT5ESMN1; SMN2CA9 | |
| SCHEMBL14400883 | 0.85 | CA9 (0.44) | GPBAR1LMNANT5ESMN1; SMN2CA9 | |
| SCHEMBL14398798 | 0.85 | CA9 (0.44) | GPBAR1LMNANT5ESMN1; SMN2CA9 | |
| SCHEMBL14374405 | 0.85 | CA9 (0.44) | GPBAR1LMNANT5ESMN1; SMN2CA9 | |
| SCHEMBL13910944 | 0.85 | CA9 (0.44) | GPBAR1LMNANT5ESMN1; SMN2CA9 | |
| SCHEMBL5439771 | 0.85 | CA9 (0.44) | GPBAR1LMNANT5ESMN1; SMN2CA9 | |
| SCHEMBL14398336 | 0.82 | GPBAR1 (0.60) | GPBAR1LMNANT5ESMN1; SMN2CA9 | |
| SCHEMBL5446921 | 0.82 | GPBAR1 (0.60) | GPBAR1LMNANT5ESMN1; SMN2CA9 | |
| SCHEMBL13293168 | 0.82 | GPBAR1 (0.60) | GPBAR1LMNANT5ESMN1; SMN2CA9 | |
| SCHEMBL14374319 | 0.80 | CA9 (0.42) | GPBAR1LMNANT5ESMN1; SMN2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232577-A1 | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin | ADVANCED LIFE SCIENCES, INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232577-A1 | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin | BET1, PGGT1B, BRCA1 | MGAM 3979/4885GAA 2059/4885SI 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.